|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reinersman JM, Johnson ML, Riely GJ,
Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G,
Lau C, et al: Frequency of EGFR and KRAS mutations in lung
adenocarcinomas in African Americans. J Thorac Oncol. 6:28–31.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gahr S, Stoehr R, Geissinger E, Ficker JH,
Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C,
Rieker RJ, et al: EGFR mutational status in a large series of
Caucasian European NSCLC patients: Data from daily practice. Br J
Cancer. 109:1821–1828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
NC CN NCCN Clinical Practice Guidelines in
Oncology NSCLC (version 7 2015). 2015, http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfJuly
16–2015
|
|
6
|
Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K,
Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, et al: The
International Association for the Study of Lung Cancer consensus
statement on optimizing management of EGFR mutation-positive
non-small cell lung cancer: Status in 2016. J Thorac Oncol.
11:946–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn
JS, Park K and Ahn MJ: AZD9291 overcomes T790 M-mediated resistance
through degradation of EGFR(L858R/T790M) in non-small cell lung
cancer cells. Invest New Drugs. 34:407–415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oxnard GR, Arcila ME, Sima CS, Riely GJ,
Chmielecki J, Kris MG, Pao W, Ladanyi M and Miller VA: Acquired
resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung
cancer: Distinct natural history of patients with tumors harboring
the T790M mutation. Clin Cancer Res. 17:1616–1622. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Finlay MR, Anderton M, Ashton S, Ballard
P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S,
Campbell A, et al: Discovery of a potent and selective EGFR
inhibitor (AZD9291) of both sensitizing and T790M resistance
mutations that spares the wild type form of the receptor. J Med
Chem. 57:8249–8267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
FDA FDA approves new pill to treat certain
patients with non-small cell lung cancer, 2015. Available at
Osimertinib in models of EGFR-mutant NSCLC brain metastases.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htmNovember
13–2015
|
|
13
|
Ramalingam SS, Reungwetwattana T and
Chewaskulyong B: Osimertinib versus standard-of-care EGFR-TKI as
first-line treatment in patients with EGFRm advanced NSCLC: FLARA.
Presented at the ESMO Congress, Madrid, (abstract LBA2). 2017,
https://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/Osimertinib-vs-standard-of-care-SoC-EGFR-TKI-as-first-line-therapy-in-patients-pts-with-EGFRm-advanced-NSCLC-FLAURA
|
|
14
|
Delaney G, Barton M, Jacob S and Jalaludin
B: A model for decision making for the use of radiotherapy in lung
cancer. Lancet Oncol. 4:120–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bokobza SM, Jiang Y, Weber AM, Devery AM
and Ryan AJ: Short-course treatment with gefitinib enhances
curative potential of radiation therapy in a mouse model of human
non-small cell lung cancer. Int J Radiat Oncol Biol Phys.
88:947–954. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang S, Zheng X, Huang H, Wu K, Wang B,
Chen X and Ma S: Afatinib increases sensitivity to radiation in
non-small cell lung cancer cells with acquired EGFR T790M mutation.
Oncotarget. 6:5832–5845. 2015.PubMed/NCBI
|
|
17
|
Kriegs M, Gurtner K, Can Y, Brammer I,
Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob TJ, et al:
Radiosensitization of NSCLC cells by EGFR inhibition is the result
of an enhanced p53-dependent G1 arrest. Radiother Oncol.
115:120–127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ready N, Jänne PA, Bogart J, Dipetrillo T,
Garst J, Graziano S, Gu L, Wang X, Green MR and Vokes EE: Cancer,
Leukemia Group B, Chicago, IL: Chemoradiotherapy and gefitinib in
stage III non-small cell lung cancer with epidermal growth factor
receptor and KRAS mutation analysis: Cancer and leukemia group B
(CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol.
5:1382–1390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kelly K, Chansky K, Gaspar LE, Albain KS,
Jett J, Ung YC, Lau DH, Crowley JJ and Gandara DR: Phase III trial
of maintenance gefitinib or placebo after concurrent
chemoradiotherapy and docetaxel consolidation in inoperable stage
III non-small-cell lung cancer: SWOG S0023. J Clin Oncol.
26:2450–2456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choong NW, Mauer AM, Haraf DJ, Lester E,
Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, et al:
Phase I trial of erlotinib-based multimodality therapy for
inoperable stage III non-small cell lung cancer. J Thorac Oncol.
3:1003–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Komaki R, Blumenschein GR, Wistuba II, Lee
JJ, Allen P, Wei X, Welsh J, O'Reilly M, Herbst RS, Tang X, et al:
Phase II trial of erlotinib and radiotherapy following
chemoradiotherapy for patients with stage III non-small cell lung
cancer. J Clin Oncol. 29((Suppl 15)): 70202011. View Article : Google Scholar
|
|
22
|
Kalvass JC, Maurer TS and Pollack GM: Use
of plasma and brain unbound fractions to assess the extent of brain
distribution of 34 drugs: Comparison of unbound concentration
ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos.
35:660–666. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Casal Rubio J, Fírvida-Pérez JL,
Lázaro-Quintela M, Barón-Duarte FJ, Alonso-Jáudenes G, Santomé L,
Afonso-Afonso FJ, Amenedo M, Huidobro G, Campos-Balea B, et al: A
phase II trial of erlotinib as maintenance treatment after
concurrent chemoradiotherapy in stage III non-small-cell lung
cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study. Cancer
Chemother Pharmacol. 73:451–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu Y, Zheng Y, Sun X, Yu X, Gu J, Wu W,
Zhang G, Hu J, Sun W and Mao W: Concurrent radiotherapy with
gefitinib in elderly patients with esophageal squamous cell
carcinoma: Preliminary results of a phase II study. Oncotarget.
6:38429–38439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park SY, Kim YM and Pyo H: Gefitinib
radiosensitizes non-small cell lung cancer cells through inhibition
of ataxia telangiectasia mutated. Mol Cancer. 9:2222010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Das AK, Sato M, Story MD, Peyton M, Graves
R, Redpath S, Girard L, Gazdar AF, Shay JW, Minna JD, et al:
Non-small-cell lung cancers with kinase domain mutations in the
epidermal growth factor receptor are sensitive to ionizing
radiation. Cancer Res. 66:9601–9608. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Das AK, Chen BP, Story MD, Sato M, Minna
JD, Chen DJ and Nirodi CS: Somatic mutations in the tyrosine kinase
domain of epidermal growth factor receptor (EGFR) abrogate
EGFR-mediated radioprotection in non-small cell lung carcinoma.
Cancer Res. 67:5267–5274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dittmann K, Mayer C, Fehrenbacher B,
Schaller M, Kehlbach R and Rodemann HP: Nuclear EGFR shuttling
induced by ionizing radiation is regulated by phosphorylation at
residue Thr654. FEBS Lett. 584:3878–3884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dittmann K, Mayer C, Fehrenbacher B,
Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R and Rodemann HP:
Radiation-induced epidermal growth factor receptor nuclear import
is linked to activation of DNA-dependent protein kinase. J Biol
Chem. 280:31182–31189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Toulany M, Kasten-Pisula U, Brammer I,
Wang S, Chen J, Dittmann K, Baumann M, Dikomey E and Rodemann HP:
Blockage of epidermal growth factor receptor-phosphatidylinositol
3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated
human tumor cells in vitro by affecting DNA repair. Clin Cancer
Res. 12:4119–4126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rodemann HP, Dittmann K and Toulany M:
Radiation-induced EGFR-signaling and control of DNA-damage repair.
Int J Radiat Biol. 83:781–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kriegs M, Kasten-Pisula U, Rieckmann T,
Holst K, Saker J, Dahm-Daphi J and Dikomey E: The epidermal growth
factor receptor modulates DNA double-strand break repair by
regulating non-homologous end-joining. DNA Repair (Amst).
9:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Myllynen L, Rieckmann T, Dahm-Daphi J,
Kasten-Pisula U, Petersen C, Dikomey E and Kriegs M: In tumor cells
regulation of DNA double strand break repair through EGF receptor
involves both NHEJ and HR and is independent of p53 and K-Ras
status. Radiother Oncol. 101:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Löbrich M, Shibata A, Beucher A, Fisher A,
Ensminger M, Goodarzi AA, Barton O and Jeggo PA: gammaH2AX foci
analysis for monitoring DNA double-strand break repair: Strengths,
limitations and optimization. Cell Cycle. 9:662–669. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lord CJ and Ashworth A: The DNA damage
response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li B, Yuan M, Kim IA, Chang CM, Bernhard
EJ and Shu HK: Mutant epidermal growth factor receptor displays
increased signaling through the phosphatidylinositol-3 kinase/AKT
pathway and promotes radioresistance in cells of astrocytic origin.
Oncogene. 23:4594–4602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun Y, Moretti L, Giacalone NJ, Schleicher
S, Speirs CK, Carbone DP and Lu B: Inhibition of JAK2 signaling by
TG101209 enhances radiotherapy in lung cancer models. J Thorac
Oncol. 6:699–706. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dent P, Yacoub A, Contessa J, Caron R,
Amorino G, Valerie K, Hagan MP, Grant S and Schmidt-Ullrich R:
Stress and radiation-induced activation of multiple intracellular
signaling pathways. Radiat Res. 159:283–300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Walter AO, Sjin RT, Haringsma HJ, Ohashi
K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, et al:
Discovery of a mutant-selective covalent inhibitor of EGFR that
overcomes T790M-mediated resistance in NSCLC. Cancer Discov.
3:1404–1415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ercan D, Xu C, Yanagita M, Monast CS,
Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova
EV, et al: Reactivation of ERK signaling causes resistance to EGFR
kinase inhibitors. Cancer Discov. 2:934–947. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cortot AB, Repellin CE, Shimamura T,
Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray
NS and Jänne PA: Resistance to irreversible EGF receptor tyrosine
kinase inhibitors through a multistep mechanism involving the IGF1R
pathway. Cancer Res. 73:834–843. 2013. View Article : Google Scholar : PubMed/NCBI
|
